Initial clinical trial data highlight the potential for a new approach to cancer vaccines to treat patients with a wide range of KRAS mutations, Elicio Therapeutics CEO Robert Connelly explains.

The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

At age 50, Alexandria Forbes founded MeiraGTx, a gene therapy company with six clinical programs and innovative technology to control genes with pills. (Gene-based medicine is typically administered via the injection of cells through a vector.)

Recce Pharmaceuticals, a biotechnology company focused on the global antibiotic-resistant patient population. This new class of synthetic antibiotics takes a broad-spectrum approach to kill bacterial infections, which continue to mutate, rendering existing antibiotics ineffective. The founding inventor of Recce is Dr. Graham Melrose, the grandfather of James, who has grown this idea into one of the top-performing biotech stocks in Australia.

Philipp Spycher has an extensive background in bioconjugation and ADCs. He obtained his master’s degree and Ph.D. from ETH Zurich in material science and protein engineering. During his post-doctoral work at Paul Scherrer Institute, he introduced the novel approach of using transglutaminases for antibody conjugation, which led to the discovery of what is now called Araris linker technology.

Meanwhile, Aphaia Pharma is also developing a promising drug candidate for weight loss, APH-012, with a focus on why L-cells – nutrient-sensing cells in the distal part of the intestine – in patients with metabolic disease are largely deprived from contact with food, as this leads to a lack of endocrine, neuroendocrine, and neuronal stim

Ambrx is the pioneer of an expanded genetic code technology platform for synthetic amino acid incorporation into proteins at any position, providing a unique

Xalud is using a non-viral DNA plasmid vector to restore homeostasis and treat pathologic inflammation within the immune system. Howard Rutman, M.D., MBA, Chief Medical Officer at Xalud Therapeutics